Sickle cell disease (SCD) is the most common type of hereditary anemia with a particularly high prevalence in sub-Saharan Africa. More than 230,000 children are affected in this geographical region every year, making up 80% of the global total.[1] SCD is characterized by the abnormal polymerization of the β-globin protein, resulting in obstruction to the microcirculation and tissue hypoxia. Cerebral hemorrhage is quite uncommon, with an incidence ranging from 0.5 to 2%. Cerebrovascular complications contribute significantly to the morbidity and mortality of the disease.[2] [3] [4] Variable risk factors include acute hypertension, blood transfusion, use of steroids, and nonsteroidal anti-inflammatory drugs (NSAIDs).[5]
No takes yet. Share an insight, caveat, or question.
Valluzzi et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: